Redmile Group LLC Sells 54,467 Shares of LivaNova PLC (NASDAQ:LIVN)

Redmile Group LLC cut its holdings in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 5.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 875,039 shares of the company's stock after selling 54,467 shares during the period. LivaNova makes up approximately 2.7% of Redmile Group LLC's holdings, making the stock its 15th biggest position. Redmile Group LLC owned about 1.61% of LivaNova worth $45,975,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the business. Hexagon Capital Partners LLC lifted its stake in LivaNova by 117.8% during the second quarter. Hexagon Capital Partners LLC now owns 684 shares of the company's stock valued at $37,000 after buying an additional 370 shares in the last quarter. Fifth Third Bancorp raised its holdings in shares of LivaNova by 97.1% during the second quarter. Fifth Third Bancorp now owns 674 shares of the company's stock valued at $37,000 after acquiring an additional 332 shares during the period. Canada Pension Plan Investment Board purchased a new stake in shares of LivaNova in the 2nd quarter valued at approximately $88,000. Central Pacific Bank Trust Division acquired a new position in LivaNova in the 3rd quarter worth approximately $178,000. Finally, TradeLink Capital LLC purchased a new position in LivaNova during the 2nd quarter worth approximately $208,000. Institutional investors and hedge funds own 97.64% of the company's stock.

Wall Street Analysts Forecast Growth

LIVN has been the subject of a number of research analyst reports. Baird R W upgraded LivaNova from a "hold" rating to a "strong-buy" rating in a report on Tuesday, September 17th. Needham & Company LLC reissued a "buy" rating and set a $75.00 price target on shares of LivaNova in a research report on Monday, November 25th. Robert W. Baird raised their price objective on LivaNova from $66.00 to $72.00 and gave the stock an "outperform" rating in a research report on Thursday, October 31st. The Goldman Sachs Group assumed coverage on LivaNova in a research note on Friday, October 4th. They set a "buy" rating and a $65.00 target price on the stock. Finally, Mizuho reduced their price target on shares of LivaNova from $80.00 to $70.00 and set an "outperform" rating for the company in a research report on Thursday, October 31st. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $69.17.

LivaNova Stock Down 1.3 %

Shares of LIVN traded down $0.69 during midday trading on Thursday, reaching $50.50. 496,338 shares of the stock were exchanged, compared to its average volume of 608,269. The company has a market cap of $2.74 billion, a price-to-earnings ratio of 120.24 and a beta of 0.98. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. LivaNova PLC has a 12-month low of $43.15 and a 12-month high of $64.47. The firm has a 50 day simple moving average of $52.25 and a 200-day simple moving average of $51.94.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.